SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives to enhance shareholder value, including a sale or other transaction, but there is no set timetable for making a decision. SRLS +3.3% premarket. (PR)
SeraCare Life Sciences (SRLS) says it will explore and evaluate potential strategic alternatives...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs